论文部分内容阅读
秋水仙酰胺是从秋水仙碱进一步合成的抗癌药物。过去秋水仙碱治疗白血病及各种肿瘤已可肯定其疗效,为抗癌药物之一,尤其对乳腺癌及急性淋巴细胞性白血病疗效较好,但有一定的毒性,有碍治疗。天津药品检验药物研究所为了减轻治疗肿瘤时对人体的毒性,从秋水仙碱提制秋水仙酰胺,应用于临床,曾对75例乳腺癌治疗近期疗效作了分析报告,并作了动物小鼠的毒性试验,发现秋水仙酰胺的毒性,在静脉为秋水仙碱的1/10,腹腔为1/20。在一定剂量条件下,对动物肿瘤的抑制作用稍高于秋水仙碱,而毒性反比秋水仙碱小10～20倍。鉴于这一点,我院试用于各类白血病的治疗,初步近期疗效报告于下: 一、药物来源:由云南制药厂从云南丽
Colchicine is an anti-cancer drug that is further synthesized from colchicine. Past colchicine treatment of leukemia and a variety of tumors have been able to confirm its efficacy as one of the anti-cancer drugs, especially for breast cancer and acute lymphoblastic leukemia better effect, but some toxicity, hinder the treatment. Tianjin Institute of Drug Testing Drugs in order to reduce the toxicity of the treatment of cancer on the human body, the colchicine from colchicine preparation of colchicine, used in clinical, had 75 cases of breast cancer treatment of recent treatment made an analysis report and made animal mice Toxicity test found colchicine amide toxicity in the vein of colchicine for 1/10, 1/20 abdominal cavity. Under certain dose conditions, the inhibitory effect on animal tumors is slightly higher than that of colchicine, while the toxicity is less than the colchicine 10 to 20 times. In view of this, our hospital trial for the treatment of various types of leukemia, the initial report of the recent efficacy of the next: First, the source of drugs: from Yunnan Pharmaceutical Factory from Yunnan